BRPI0924404A2 - composto alfa-(n-sulfonamido) acetamida como um inibidor de produção de peptídeo beta amilóide - Google Patents

composto alfa-(n-sulfonamido) acetamida como um inibidor de produção de peptídeo beta amilóide

Info

Publication number
BRPI0924404A2
BRPI0924404A2 BRPI0924404-2A BRPI0924404A BRPI0924404A2 BR PI0924404 A2 BRPI0924404 A2 BR PI0924404A2 BR PI0924404 A BRPI0924404 A BR PI0924404A BR PI0924404 A2 BRPI0924404 A2 BR PI0924404A2
Authority
BR
Brazil
Prior art keywords
sulfonamido
inhibitor
alpha
amyloid peptide
beta amyloid
Prior art date
Application number
BRPI0924404-2A
Other languages
English (en)
Inventor
John E. Starrett, Jr.
W. Gillman Kevin
E. Olson Richard
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BRPI0924404A2 publication Critical patent/BRPI0924404A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

usos de (2r)-2-[[(4-cloro fenil)sulfonil][[2-flúor-4-(1,2,4-oxadiazol-3-il)fenil]metil]amino-5,5,5-triflúor pentanamida a presente invenção provê um processo para o tratamento de trauma de cabeça, dano traumático do cérebro, e/ou demência pugilística compreendendo administração de uma quantidade terapeuticamente efetiva de (2r)-2-[[(4-cloro fenil)sulfonil][[2-flúor-4-(1,2,4-oxadiazol-3-il)fenil]metil] amino-5,5,5-triflúor pentanamida.
BRPI0924404-2A 2009-03-19 2009-03-19 composto alfa-(n-sulfonamido) acetamida como um inibidor de produção de peptídeo beta amilóide BRPI0924404A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/037639 WO2010107435A1 (en) 2009-03-19 2009-03-19 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Publications (1)

Publication Number Publication Date
BRPI0924404A2 true BRPI0924404A2 (pt) 2019-04-02

Family

ID=40940246

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924404-2A BRPI0924404A2 (pt) 2009-03-19 2009-03-19 composto alfa-(n-sulfonamido) acetamida como um inibidor de produção de peptídeo beta amilóide

Country Status (15)

Country Link
EP (1) EP2408450B1 (pt)
JP (1) JP2012520875A (pt)
KR (1) KR20110133046A (pt)
CN (1) CN102438622A (pt)
AU (1) AU2009342632A1 (pt)
BR (1) BRPI0924404A2 (pt)
CA (1) CA2755738A1 (pt)
EA (1) EA201171143A1 (pt)
ES (1) ES2406363T3 (pt)
IL (1) IL214629A0 (pt)
MX (1) MX2011009271A (pt)
NZ (1) NZ594561A (pt)
SG (1) SG173797A1 (pt)
WO (1) WO2010107435A1 (pt)
ZA (1) ZA201106206B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1465861T3 (da) 2001-12-20 2009-08-31 Bristol Myers Squibb Co Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
DE112015001826T5 (de) * 2014-04-17 2016-12-22 Sumitomo Chemical Company, Limited Verfahren zur Herstellung einer Nitroverbindung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9817348D0 (en) * 1998-08-11 1998-10-07 British Biotech Pharm Pharmaceutical use of esters
DK1465861T3 (da) * 2001-12-20 2009-08-31 Bristol Myers Squibb Co Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere
GB0313772D0 (en) * 2003-06-13 2003-07-23 Merck Sharp & Dohme Therapeutic treatment
WO2005054193A1 (en) * 2003-12-03 2005-06-16 Merck & Co. Inc. 1-alkyl-3-thio-substituted indole-2-alkynoic acids useful for the treatment for alzheimer's disease and related conditions
EP1750719A2 (en) * 2004-05-19 2007-02-14 Boehringer Ingelheim International GmbH Treatment of diseases associated with altered level of amyloid beta peptides
CA2676715A1 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP5374370B2 (ja) * 2007-08-09 2013-12-25 株式会社ヤクルト本社 新規γセクレターゼ阻害剤
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Also Published As

Publication number Publication date
IL214629A0 (en) 2011-09-27
ES2406363T3 (es) 2013-06-06
EP2408450A1 (en) 2012-01-25
SG173797A1 (en) 2011-09-29
NZ594561A (en) 2013-03-28
MX2011009271A (es) 2011-09-26
WO2010107435A1 (en) 2010-09-23
CN102438622A (zh) 2012-05-02
CA2755738A1 (en) 2010-09-23
EP2408450B1 (en) 2013-03-13
WO2010107435A8 (en) 2011-10-13
AU2009342632A1 (en) 2011-09-01
ZA201106206B (en) 2013-01-30
JP2012520875A (ja) 2012-09-10
EA201171143A1 (ru) 2012-03-30
KR20110133046A (ko) 2011-12-09

Similar Documents

Publication Publication Date Title
CO6791571A2 (es) Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos
CL2014000299A1 (es) Compuestos derivados de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2.2.1]heptan-3-carboxamidas sustituidas, inhibidores de catepsina c; composicion farmaceutica; metodo de tratamiento o prevencion; y uso para el tratamiento de enfermedades tales como asma, enfermedades alergicas, artritis reumatoidea y aterosclerosis, entre otras.
CL2014000492A1 (es) Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras
CL2007002974A1 (es) Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
BR112013017988A2 (pt) inibidores de bace-2 para o tratamento de distúrbios metabólicos
HN2011002037A (es) Dicianopiridinas alquilamino-sustituidas y sus profarmacos de ester de aminoacido
AR099354A1 (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
CO6771447A2 (es) Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina
BR112013031794A2 (pt) novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos
BR112016008593A8 (pt) composto, composição farmacêutica, método de regulação de transcrição gênica em uma célula, uso de um composto e método de inibição de reconhecimento mediado por bromodomínio de uma região de acetil lisina de uma proteína
CL2014000314A1 (es) Compuestos derivados de ciclopropanamina, inhibidores de desmetilasa especifica de lisina 1 (lsd1); medicamento que los comprende; metodo para profilaxis o tratamiento; metodo para inhibir lsd1; y su uso en la profilaxis o tratamiento de esquizofrenia, enfermedad de alzheimer, enfermedad de parkinson o corea de huntington.
BR112014004465A2 (pt) compostos e composições como inibidores de pdgfr cinase
PT2523661T (pt) Inibidores de nkcc para o tratamento de autismo
EP2718265A4 (en) PROCESS FOR THE PREPARATION OF [(3-HYDROXYPYRIDINE-2-CARBONYL-) AMINO-] ALKANIC ACIDS, ETHERS AND AMMUNES
CL2013002341A1 (es) Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
CR20140494A (es) Inhibidores de dgat1 de eter ciclico de cabeza de puente
BR112013003529A2 (pt) "composição aerada, composição de tratamento capilar método para o tratamento capilar"
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
WO2012107890A3 (en) Crystal forms of lurasidone chlorhydrate
CL2007002934A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina, inhibidores de proteina quinasa; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como trastornos metabolicos, enfermedades del sistema nervioso, alergias, asma, tr

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2518 DE 09-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]